Atlas Trials

Relapsing-Remitting Multiple Sclerosis (RRMS)

30 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Relapsing-Remitting Multiple Sclerosis (RRMS)

RecordFirmDate
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study (NCT05245344)Neuromed IRCCS2022-04-01
A Study for Tysabri Participant Preference (NCT05304520)Biogen2021-10-12
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® (NCT04115488)Polpharma Biologics S.A.2019-10-01
MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) (NCT03846219)Immunic AG2019-01-28
Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis (NCT05177523)University Hospital, Basel, Switzerland2018-09-04
Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis (NCT05242133)Cinnagen2017-12-20
Plegridy Satisfaction Study in Participants (NCT02587065)Biogen2016-02-03
Brimonidine Tartrate for the Treatment of Injection Related Erythema (NCT02568111)Biogen2016-02-01
Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis (NCT02035514)Germans Trias i Pujol Hospital2013-12-01
A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya® (NCT01705236)Novartis Pharmaceuticals2012-08-20
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone (NCT01633112)Novartis Pharmaceuticals2012-08-09
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod (NCT01499667)Novartis Pharmaceuticals2011-09-01
A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects (NCT01125475)Merck KGaA, Darmstadt, Germany2010-08-01
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients (NCT00871780)Biogen2009-08-01
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment (NCT00787657)Bayer2008-06-01
Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors (NCT01235455)Bayer2007-08-01
RNF and Betaseron® Tolerability Study (NCT00428584)EMD Serono2006-12-01

Track Relapsing-Remitting Multiple Sclerosis (RRMS) automatically

Every clearance here is in the API, with alerts when new ones post.